Caribou Biosciences, Inc. (CRBU)

Caribou Biosciences shares fell 2.92% to close at $0.62 after the company announced it is exploring strategic alternatives, a move that typically signals uncertainty about its standalone prospects. The stock traded in a wide range between $0.55 and $0.67 on heavy volume of over 33.7 million shares. The decline was compounded by a wave of analyst downgrades: Brookline Capital cut the stock to Hold, while RBC Capital and Leerink Partners both downgraded it to Market Perform with $1 price targets. The combination of strategic-alternative exploration and multiple downgrades points to a bearish near-term direction for CRBU.

Caribou Biosciences shares fell 4.62% to close at $1.14 after the company announced it is exploring strategic alternatives and discontinuing further development of its Vispa-Cel and CB-011 CAR-T programs while cutting its workforce. The stock traded between a low of $1.13 and a high of $1.22 on volume of 1,091,436 shares. The company reported having $113.8 million in cash as of June 30. The program discontinuations and strategic review signal significant uncertainty about the company's pipeline direction, weighing on investor sentiment.